Sputum test for lung cancer nears approval in Canada and Europe
This article was originally published in Clinica
A sputum test for lung cancer in high-risk patients could receive regulatory approval from Canadian authorities as early as spring 2006. The ClearSign test, developed by Perceptronix, uses AQC (automated qualitative cytometry) technology. The Vancouver, Canada-based company is also using the same technology to develop a lung cancer screening test based on buccal samples (cheek scrapings).